Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: Inhibition of de novo infection and activation of viral LTR

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Abreu, Celina M ^a,b   Price, Sarah L ^b   Shirk, Erin N ^b   Cunha, Rodrigo D ^a   Pianowski, Luiz F ^c   Clements, Janice E ^a   Tanuri, Amilcar ^a   Gama, Lucio ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Kyolab   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

12 DEOXYPHORBOL 13 ACETATE; CARBON; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DITERPENE; EFAVIRENZ; INGENOL; INGENOL 3 DODECANOATE; INGENOL 3 HEXANOATE; INGENOL 3 TRANS CINNAMATE; LAMIVUDINE; PHORBOL 13 MYRISTATE ACETATE; PROSTRATIN; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CCR5 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN;

ADULT; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; EUPHORBIA; EUPHORBIA TIRUCALLI; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LONG TERMINAL REPEAT; MALE; MEDIAN EFFECTIVE CONCENTRATION; MIDDLE AGED; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SIGNAL TRANSDUCTION; VIRUS ACTIVATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; YOUNG ADULT; CELL LINE; DRUG EFFECTS; GENETIC TRANSCRIPTION; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MONONUCLEAR CELL; PROCEDURES; UPREGULATION; VIROLOGY; VIRUS LATENCY;

ANTI-HIV AGENTS; ANTIGENS, CD4; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL LINE; DITERPENES; DOWN-REGULATION; EUPHORBIA; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; RECEPTORS, CCR5; RECEPTORS, CXCR4; TRANSCRIPTION, GENETIC; UP-REGULATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84901354407     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097257     Document Type: Article

References (79)

1. Rohr O, Marban C, Aunis D, Schaeffer E (2003) Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leukoc Biol 74: 736-749. doi:10.1189/jlb.0403180.http (Pubitemid 38040350)
2. McNamara L a, Ganesh J a, Collins KL (2012) Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-κB activation. J Virol 86: 9337-9350. doi:10.1128/JVI.00895-12
3. Eisele E, Siliciano RF (2012) Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37: 377-388. doi:10.1016/j.immuni.2012.08. 010
4. Siliciano RF, Greene WC (2011) HIV latency. Cold Spring Harb Perspect Med 1: a007096. doi:10.1101/cshperspect.a007096
5. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9: 727-728. doi:10.1038/nm880. (Pubitemid 36749221)
6. Hamer DH (2004) Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it. Curr HIV Res 2: 99-111.
7. Savarino A, Mai A, Norelli S, El Daker S, Valente S, et al. (2009) "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 6: 52. doi:10.1186/1742-4690-6-52
8. Bocklandt S, Blumberg P, Hamer D (2003) Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. Antiviral Res 59: 89-98. doi:10.1016/S0166-3542(03)00034-2. (Pubitemid 36934497)
9. Zhou M, Deng L, Lacoste V (2004) Coordination of Transcription Factor Phosphorylation and Histone Methylation by the P-TEFb Kinase during Human Immunodeficiency Virus Type 1 Transcription. J Virol 78: 13522-13533. doi:10.1128/JVI.78.24.13522 (Pubitemid 39612752)
10. Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, et al. (1997) Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 11: 2622-2632. (Pubitemid 27452386)
11. Barboric M, Nissen RM, Kanazawa S, Jabrane-ferrat N, Peterlin BM, et al. (2001) NF-κB Binds P-TEFb to Stimulate Transcriptional Elongation by RNA Polymerase II. Mol Cell 8: 327-337. (Pubitemid 32831550)
12. Cherrier T, Le Douce V, Eilebrecht S, Riclet R, Marban C, et al. (2013) CTIP2 is a negative regulator of P-TEFb. Proc Natl Acad Sci U S A 110: 12655-12660. doi:10.1073/pnas.1220136110
13. Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, et al. (1999) Immunoactivation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13: 2405-2410.
14. Vandergeeten C, Fromentin R, Chomont N (2012) The role of cytokines in the establishment, persistence and eradication of the HIV reservoir. Cytokine Growth Factor Rev 23: 143-149. doi:10.1016/j.cytogfr.2012.05.001
15. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA (2002) Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 76: 13077-13082. doi:10.1128/JVI.76.24. 13077 (Pubitemid 35386993)
16. Devadas K, Hardegen NJ, Wahl LM, Hewlett IK, Clouse K a, et al. (2004) Mechanisms for macrophage-mediated HIV-1 induction. J Immunol 173: 6735-6744. (Pubitemid 39541059)
17. Xing S, Siliciano RF (2013) Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today 18: 541-551. doi:10.1016/j.drudis.2012.12.008
18. Bouchat S, Gatot J-S, Kabeya K, Cardona C, Colin L, et al. (2012) Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS 26: 1473-1482. doi:10.1097/QAD.0b013e32835535f5
19. Goel G, Makkar HPS, Francis G, Becker K (2007) Phorbol esters: structure, biological activity, and toxicity in animals. Int J Toxicol 26: 279-288. doi:10.1080/10915810701464641 (Pubitemid 47174587)
20. McKernan LN, Momjian D, Kulkosky J (2012) Protein Kinase C: One Pathway towards the Eradication of Latent HIV-1 Reservoirs. Adv Virol 2012: 805347. doi:10.1155/2012/805347
21. Colin L, Van Lint C (2009) Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6: 111. doi:10.1186/1742-4690-6-111
22. Zayed S, Hafez A, Adolf W, Hecker E (1977) New tigliane and daphnane derivatives from Pimelea prostrata and Pimelea simplex. Experientia 33: 1554-1555. (Pubitemid 8237064)
23. Kulkosky J, Sullivan J, Xu Y, Souder E, Hamer DH, et al. (2004) Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. AIDS Res Hum Retroviruses 20: 497-505. doi:10.1089/ 088922204323087741 (Pubitemid 38720963)
24. Biancotto A, Grivel J (2004) Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 78: 10507-10515. doi:10.1128/JVI.78.19.10507 (Pubitemid 39258376)
25. Rullas J, Bermejo M, García-Pérez J, Beltán M, González N, et al. (2004) Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antivir Ther 9: 545-554. (Pubitemid 39150212)
26. Yang H, Xing S, Shan L (2009) Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin ... 119. doi:10.1172/JCI39199DS1
27. Sánchez-Duffhues G, Vo MQ, Pérez M, Calzado MA, Moreno S, et al. (2011) Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs. Curr Drug Targets 12: 348-356.
28. Yoshida M, Heike Y, Ohno S, Ikekawa T, Wakasugi H (2003) Involvement of PKC betaII in anti-proliferating action of a new antitumor compound gnidimacrin. Int J Cancer 105: 601-606. doi:10.1002/ijc.11157 (Pubitemid 36687726)
29. Hezareh M, Moukil MA, Szanto I, Pondarzewski M, Mouche S, et al. (2004) Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms. Antivir Chem Chemother 15: 207-222. (Pubitemid 39145468)
30. Huang L, Ho P, Yu J, Zhu L, Lee K-H, et al. (2011) Picomolar dichotomous activity of gnidimacrin against HIV-1. PLoS One 6: e26677. doi:10.1371/journal. pone.0026677
31. Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, et al. (2010) Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 5: e11160. doi:10.1371/journal.pone.0011160
32. Boto WM, Brown L, Chrest J, Adler WH (1991) Distinct modulatory effects of bryostatin 1 and staurosporine on the biosynthesis and expression of the HIV receptor protein (CD4) by T cells. Cell Regul 2: 95-103.
33. Wender P, Kee J, Warrington J (2008) Practical Synthesis of prostratin, DPP, and their Analogs, Adjuvant leads against latent HIV. Science (80-) 320: 649-652. doi:10.1126/science.1154690.Practical
34. Wender P, Baryza J (2011) Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proc Natl Acad Sci U S A 108: 6721-6726. doi:10.1073/pnas.1015270108
35. Williams S a, Chen L-F, Kwon H, Fenard D, Bisgrove D, et al. (2004) Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 279: 42008-42017. doi:10.1074/jbc.M402124200
36. Jassbi AR (2006) Chemistry and biological activity of secondary metabolites in Euphorbia from Iran. Phytochemistry 67: 1977-1984. doi:10.1016/j.phytochem.2006.06.030
37. Barrero R a, Chapman B, Yang Y, Moolhuijzen P, Keeble-Gagnère G, et al. (2011) De novo assembly of Euphorbia fischeriana root transcriptome identifies prostratin pathway related genes. BMC Genomics 12: 600. doi:10.1186/1471-2164-12-600
38. Jørgensen L, McKerrall SJ, Kuttruff CA, Ungeheuer F, Felding J, et al. (2013) 14-step synthesis of (+)-ingenol from (+)-3-carene. Science 341: 878-882. doi:10.1126/science.1241606
39. Hampson P, Wang K, Lord JM (2005) Treatment of actinic keratoses acute myeloid leukemia therapy treatment of basal cell carcinoma protein kinase C activator. Drugs Future 30: 1003-1005. (Pubitemid 43094085)
40. Fujiwara M, Okamoto M, Ijichi K, Tokuhisa K, Hanasaki Y, et al. (1998) Upregulation of HIV-1 replication in chronically infected cells by ingenol derivatives. Arch Virol 143: 2003-2010. (Pubitemid 28537100)
41. Fujiwara M, Ijichi K, Tokuhisa K, Katsuura K, Shigeta S, et al. (1996) Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate. Antimicrob Agents Chemother 40: 271-273.
42. Blanco-Molina M, Tron GC, Macho a, Lucena C, Calzado M a, et al. (2001) Ingenol esters induce apoptosis in Jurkat cells through an AP-1 and NF-kappaB independent pathway. Chem Biol 8: 767-778. (Pubitemid 32752456)
43. Ersvaer E, Kittang AO, Hampson P, Sand K, Gjertsen BT, et al. (2010) The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity. Toxins (Basel) 2: 174-194. doi:10.3390/toxins2010174
44. Kedei N, Lundberg D, Toth A, Welburn P (2004) Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 64: 3243-3255. (Pubitemid 38581429)
45. Norman R (2013) Long-term follow-up studies of ingenol mebutate gel for the treatment of actinic keratosis. JAMA Dermatol 149: 666-670. doi:10.1001/jamadermatol.2013.2766
46. Ali FR, Wlodek C, Lear JT (2012) The Role of Ingenol Mebutate in the Treatment of Actinic Keratoses. Dermatol Ther (Heidelb) 2: 8. doi:10.1007/s13555-012-0008-4
47. Nirmala M, Samundeeswari A, Sankar P (2011) Natural plant resources in anticancer therapy-a review. Res Plant Biol 1: 1-14.
48. Harada S, Koyanagi Y, Yamamoto N (1985) Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229: 563-566. (Pubitemid 16239336)
49. Shimamura T, Li D, Ji H, Haringsma H (2008) Hsp90 Inhibition Suppresses Mutant EGFR-T790M signaling and overcome kinase inhibitor resistance. Cancer Res 68: 5827-5838. doi:10.1158/0008-5472.CAN-07-5428.Hsp90
50. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206: 1273-1289. doi:10.1084/jem.20090378
51. Jordan A, Bisgrove D, Verdin E (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22: 1868-1877. doi:10.1093/emboj/cdg188 (Pubitemid 36460143)
52. Clouse KA, Powell D, Washington I, Poli G, Strebel K, et al. (1989) Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 142: 431-438. (Pubitemid 19039959)
53. Perez VL, Rowe T, Justement JS, Butera ST, June CH, et al. (1991) An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation. J Immunol 147: 3145-3148.
54. Folks TM, Justement J, Kinter a, Dinarello C a, Fauci a S (1987) Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238: 800-802.
55. Chiang PK, McCann PP, Lane JR, Pankaskie MC, Burke DS, et al. (1996) Antihuman Immunodeficiency Virus (HIV-1) Activities of Inhibitors of Polyamine Pathways. J Biomed Sci 3: 78-81.
56. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E (2009) Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5: e1000495. doi:10.1371/journal.ppat.1000495
57. Fernandez G, Zeichner SL (2010) Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J 7: 266. doi:10.1186/1743-422X-7- 266
58. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot J-S, et al. (2009) Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 4: e6093. doi:10.1371/journal.pone.0006093
59. Capo C, Gallais H, Unite JM (2000) Impact of highly active anti-retroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients.
60. Chun TW, Stuyver L, Mizell SB, Ehler L a, Mican J a, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94: 13193-13197. (Pubitemid 27518498)
61. Buss N, Cammack N (2001) Measuring the effectiveness of antiretroviral agents. Antivir Ther 6: 1-7. (Pubitemid 33704477)
62. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF (2014) New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med: 1-6. doi:10.1038/nm.3489
63. Hong K, Sung H, Kim Y, Soon S (2011) Ingenol Protects Human T Cells From HIV-1 Infection. Public Heal Res Perspect 2: 109-114. doi:10.1016/j.phrp.2011. 07.001
64. Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, et al. (2011) In Vitro Phenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors. Antimicrob Agents Chemother 56: 137-139. doi:10.1128/AAC.05313-11
65. Huet T, Kerbarh O, Schols D, Clayette P, Gauchet C, et al. (2010) Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 54: 134-142. doi:10.1128/AAC.00827-09
66. Pedersen OS, Pedersen EB (1999) Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom. Antivir Chem Chemother 10: 285-314.
67. Schinazi RF, Sommadossi J, Saalmann V, Cannon DL, Xie M, et al. (1990) Activities of 3′-Azido-3′-deoxythymidine Nucleotide dimers in primary Lymphocytes Infected with Human Immunodeficiency Virus Type 1. Antimicrob Agents Chemother 34: 1061-1067. doi:10.1128/AAC.34.6.1061.Updated (Pubitemid 20177356)
68. Gupta A, Zhang Y, Unadkat JD, Mao Q (2004) HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2). J Pharmacol Exp Ther 310: 334-341. doi:10.1124/jpet.104.065342. glucuronide (Pubitemid 38812728)
69. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, et al. (2001) Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98: 3006-3015. doi:10.1182/blood.V98.10.3006
70. Warrilow D, Gardner J, Darnell G a, Suhrbier A, Harrich D (2006) HIV type 1 inhibition by protein kinase C modulatory compounds. AIDS Res Hum Retroviruses 22: 854-864. doi:10.1089/aid.2006.22.854 (Pubitemid 44757161)
71. Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, et al. (2007) Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 25: 473-481. doi:10.1016/j.molcel.2007.01.017 (Pubitemid 46206139)
72. Friedman J, Cho W-K, Chu CK, Keedy KS, Archin NM, et al. (2011) Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol 85: 9078-9089. doi:10.1128/JVI.00836-11
73. Márquez N, Calzado M a, Sánchez-Duffhues G, Pérez M, Minassi A, et al. (2008) Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation. Biochem Pharmacol 75: 1370-1380. doi:10.1016/j.bcp.2007.12.004
74. Macián F, López-Rodríguez C, Rao a (2001) Partners in transcription: NFAT and AP-1. Oncogene 20: 2476-2489. doi:10.1038/sj.onc. 1204386
75. Contreras X, Barboric M, Lenasi T, Peterlin BM (2007) HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog 3: 1459-1469. doi:10.1371/journal.ppat.0030146 (Pubitemid 350085610)
76. Cimo A-M, Ahmed Z, McIntyre BW, Lewis DE, Ladbury JE (2013) CD25 and CD69 induction by α4β1 outside-in signalling requires TCR early signalling complex proteins. Biochem J 454: 109-121. doi:10.1042/BJ20130485
77. Hashemi BB, Penkala JE, Vens C, Huls H, Cubbage M, et al. (1999) T cell activation responses are differentially regulated during clinorotation and in spaceflight. FASEB J 13: 2071-2082. (Pubitemid 29517637)
78. Migueles S, Osborne C, Royce C (2008) Lytic Granule Loading of CD8+ T Cells is requires for HIV-infected Cell Elimination Associated with Immune Control. Immunity 29: 1009-1021. doi:10.1016/j.immuni.2008.10.010.Lytic
79. Spina C a, Anderson J, Archin NM, Bosque A, Chan J, et al. (2013) An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients. PLoS Pathog 9: e1003834. doi:10.1371/journal.ppat.1003834